Home > Insider Trading > Filing (0000950170-24-098719)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1609809	Seres Therapeutics Inc.	MCRB	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1435744	Thomas Desrosier	C/O Seres Therapeutics, Inc. 101 Cambridge Park Drive Cambridge MA 02140	Chief Legal Officer And Evp	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-08-15	2,656	$0.00	125,046	No	4	M	Direct
Common Stock	Disposition	2024-08-16	873	$0.84	124,173	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2024-08-15	2,656	$0.00	2,656	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
26,563			No	4	M	Direct

Footnotes

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $0.8863, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.